T assays were conducted, and the mean percent relative activity is reported (see text). A dose response from a single assay of the three is presented here as representative data. e Representative nonconstrained dose?response curves of ABP 501 (red), adalimumab (US) (black), and adalimumab (EU) (blue) showing binding to FcRn. Each point is a mean of three replicates ?standard deviation. Adalimumab
Terase InhibitorC1 1205-01 (North American study) [36, 37]2/Randomized, doubleblind, placebocontrolledOpen-label extension39 patients (63 ) reported C1 AE Headache and nasopharyngitis most common AEs 10 patients (14 ) reported serious AEs, of whom 8 patients reported HAE attacks; 7 serious AEs reported in 4 patients included vertigo, pneumonia, urosepsis occurring twice and itching of the lips a